At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BBLG Bone Biologics Corp
Trading 02-26 09:58:03 EST
0.9570
+0.0266
+2.86%
High0.9800
Low0.9350
Vol9.50K
Open0.9350
D1 Closing0.9304
Amplitude4.84%
Mkt Cap2.36M
Tradable Cap2.31M
Total Shares2.46M
T/O9.10K
T/O Rate0.39%
Tradable Shares2.41M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
data is loading...
Bone Biologics Corp reports results for the quarter ended September 30 - Earnings Summary
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.